Apigenin was reported to sensitize human CD44+ prostate cancer stem cells to cisplatin therapy by enhancing the cytotoxic and apoptotic effects of cisplatin through Bcl-2 regulation. The gene discussed is BCL2; the disease is prostate carcinoma.